Epiomic Epidemiology Series: Parkinson’s disease forecast in 19 major markets 2018–2028

November 2017 | 78 pages | ID: ED20B7B2CBBEN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Parkinson’s Disease in 19 Major Markets

Parkinson’s disease (PD) is a neurodegenerative disorder that seriously affects everyday activities. PD is an age-related, progressive disease characterised by the damage to and death of dopaminergic neurons in the substantia nigra, as well as other regions of the brain. This results in the onset and development of various motor and non-motor manifestations that lead to disability and significantly deteriorate patient quality of life. Studies conducted over the last two decades have revealed the complex and multifactorial nature of the disease.

This report provides the current prevalent population for Parkinson’s disease across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Poland, Netherlands, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, patient populations with the appropriate stages of Parkinson’s disease, as well as several of the main symptoms and co-morbidities of Parkinson’s disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Parkinson’s disease include:

• Dementia
• Depression
• Psychosis
• REM sleep behaviour disorder
• Constipation
• Gastrointestinal motility dysfunction
• Orthostatic hypotension
• Sialorrhoea
• Fatigue

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Parkinson’s disease market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Parkinson’s disease and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Parkinson’s disease’s prevalent population.
• Identify sub-populations within Parkinson’s disease which require treatment.
• Gain an understanding of the specific markets that have the largest number of Parkinson’s disease patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR PARKINSON’S DISEASE

FEATURES OF PARKINSON’S DISEASE PATIENTS

COMORBID CONDITIONS OF PARKINSON’S DISEASE PATIENTS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN ANALYSIS PUBLICATIONS

BLACK SWAN ANALYSIS ONLINE PATIENT-BASED DATABASES

PATIENT-BASED OFFERING

ONLINE PRICING DATA & PLATFORMS

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Comparison between original and modified Hoehn & Yahr scales
Table 2. Prevalence of Parkinson’s Disease, total (000s)
Table 3. Prevalence of Parkinson’s Disease, males (000s)
Table 4. Prevalence of Parkinson’s Disease, females (000s)
Table 5. PD Patients by Type of Diagnosis, total (000s)
Table 6. PD Patients by Hoehn & Yahr Stage, total (000s)
Table 7. PD Patients by UPDRS Thought Disorder Subscale Score, No Disorder, total (000s)
Table 8. PD Patients by UPDRS Thought Disorder Subscale Score, Vivid Dreams, total (000s)
Table 9. PD Patients by UPDRS Thought Disorder Subscale Score, Hallucinations with Insight, total (000s)
Table 10. PD Patients by UPDRS Thought Disorder Subscale Score, Psychosis, total (000s)
Table 11. PD Patients with Dementia, total (000s)
Table 12. PD Patients with Neuropathy (Utah Early Neuropathy Scale), total (000s)
Table 13. PD Patients with Symptomatic Neuropathy (Utah Early Neuropathy Scale), total (000s)
Table 14. PD Patients with Somatoform Disorder (SFMD), total (000s)
Table 15. Abbreviations and acronyms used in the report
Table 16. USA Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 17. USA Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 18. Canada Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 19. Canada Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 20. France Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 21. France Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 22. Germany Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 23. Germany Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 24. Italy Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 25. Italy Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 26. Spain Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 27. Spain Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 28. UK Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 29. UK Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 30. Russia Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 31. Russia Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 32. Poland Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 33. Poland Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 34. Netherlands Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 35. Netherlands Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 36. Turkey Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 37. Turkey Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 38. Japan Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 39. Japan Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 40. China Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 41. China Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 42. South Korea Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 43. South Korea Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 44. India Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 45. India Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 46. Australia Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 47. Australia Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 48. Brazil Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 49. Brazil Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 50. Mexico Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 51. Mexico Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)
Table 52. Argentina Prevalence of Parkinson’s Disease by 5-yr age cohort, males (000s)
Table 53. Argentina Prevalence of Parkinson’s Disease by 5-yr age cohort, females (000s)